Biopharma Stocks Transformative Innovation for the Future of Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
EF Hutton Starts Citius Pharmaceuticals (CTXR) at Buy
July 15, 2024 9:35 AM EDTEF Hutton analyst Jason Kolbert initiates coverage on Citius Pharmaceuticals (NASDAQ: CTXR) with a Buy rating and a price target of $6.00.
The analyst comments "Low-Risk and High-Reward. Citius has two late-stage therapeutics, Mino-Lok (MLT) and LYMPHIR. Both products have demonstrated efficacy and safety and are in the final stages of the approval process.... More
